Regeneron (#1342)
Laufzeit: 01.01.2021 - 31.12.2040
imported
Kurzfassung
Phase I/II FIH Study of REGN5458 (anti-BCMA x andti-CD3 bispecific antibody) in patients with relapsed or refractory multiple myeloma
Laufzeit: 01.01.2021 - 31.12.2040
Phase I/II FIH Study of REGN5458 (anti-BCMA x andti-CD3 bispecific antibody) in patients with relapsed or refractory multiple myeloma